id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-332827-gll4nqdd	Peixe, Paula	Hepatology in the COVID Era: Another C Virus, again Challenging the Liver	2020-04-30		.txt	text/plain	3989	221	52	In published series, liver disease was not identified as a risk factor for SARS-Cov2 infection [11] [12] [13] [14] [15] . The authors state that NAFLD patients also had a higher risk of progression to severe COVID-19 and present an increased viral clearance time. Immune-mediated liver diseases, particularly autoimmune hepatitis, have not been mentioned as risk factors for COVID-19, but the immunosuppressive treatment required has triggered fears about the risk of infection in patients. Extensive records and targeted studies are needed to explore multiple open-ended questions such as the severity and mortality of COVID-19 and episodes of acute-on-chronic or decompensation associated with the presence of this disease (ascites, hepatic encephalopathy, digestive bleeding, kidney dysfunction, and the risk of infection) or the response to treatment [25, 26] . However, it is not yet possible to say whether transplantation-associated immunosuppression can alter the predisposition for the acquisition of SARS-Cov2 infection or how COVID-19 evolves in these patients.	./cache/cord-332827-gll4nqdd.txt	./txt/cord-332827-gll4nqdd.txt